Research Articles | Page 19 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia Jul 2023 Annals of Hematology Aplastic Anemia
MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? Jun 2020 Best practice & research. Clinical haematology Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN)
MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge Apr 2019 BMJ Case Reports Myelodysplastic Syndromes (MDS)
Management of myelodysplastic syndromes after failure of response to hypomethylating agents May 2019 Therapeutic Advances in Hematology Myelodysplastic Syndromes (MDS)
Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole? Sep 2020 Expert Review of Hematology Myelodysplastic Syndromes (MDS)
Management of aplastic anemia after failure of frontline immunosuppression Jul 2019 Expert Review of Hematology Aplastic Anemia
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes Sep 2020 Blood Myelodysplastic Syndromes (MDS)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Sep 2024 The Lancet Haematology Myelodysplastic Syndromes (MDS)
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Jul 2024 Lancet Hematology Myelodysplastic Syndromes (MDS)
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough Jun 2023 American Journal of Hematology Myelodysplastic Syndromes (MDS)